5-Chloro-N-(1-methylethyl)-6-[4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidin-1-yl]pyridine-3-carboxamide | 345583-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-Chloro-N-(1-methylethyl)-6-[4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidin-1-yl]pyridine-3-carboxamide
• 英文别名: 5-chloro-6-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidin-1-yl]-N-propan-2-ylpyridine-3-carboxamide
• CAS: 345583-59-7
• 化学式: C₂₃H₂₇ClN₄O₂
• 分子量: 426.946
• InChiKey: JOPRQNVIXATNRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
  申请人：——

  公开号：US20030040513A1

  公开（公告）日：2003-02-27

  The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R 1 and R 2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

  该发明提供了一般式（I）中的哌啶化合物，其中A、B、X、Y、Z、R、R1和R2如规范中所定义，它们的用途作为药物、含有它们的组合物以及它们的制备方法。
• DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1165530A2

  公开（公告）日：2002-01-02
• NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES
  申请人：AstraZeneca AB

  公开号：EP1242396A1

  公开（公告）日：2002-09-25
• US6812226B2
  申请人：——

  公开号：US6812226B2

  公开（公告）日：2004-11-02
• [EN] DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES DIHETERO-SUBSTITUES
  申请人：PROCTER & GAMBLE

  公开号：WO2000051993A2

  公开（公告）日：2000-09-08

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to formula (I): where J, M, Q, T, W, X, Z, R?1, R2, R3, R4, R4', R5, R6, R6', R7¿, m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.